title: [Acquired blood coagulation disorders].
abstract: Acquired coagulopathies regularly result from underlying diseases such as liver failure or sepsis. Optimal treatment of these underlying diseases defines longterm prognosis. In a few coagulopathies, such as immunocoagulopathies, in a relevant portion of patients an underlying disease cannot be identified. Therapeutic modulation of haemostasis aiming at the prevention of fatal bleeding or thromboembolism is able to improve the prognosis of patients with acquired coagulopathies. Most often this is the result of individualized, lab-controlled treatments, which are difficult to be studied. Within the last years the role of therapeutic modulation of haemostasis to reduce mortality was successfully studied for the first time in the frame of randomized placebo-controlled phase III studies.
authors.affiliation: Charité, Campus Virchow-Klinikum, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Augustenburger Platz 1, 13353 Berlin, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Riess
mesh_terms: D001778:Blood Coagulation Disorders / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D006487:Hemostasis; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans
chemical_list: D006490:Hemostatics